Kazuo Kobayashi

Dr. Kazuo Kobayashi

Yokohama City University, Yokohama, Kanagawa, Japan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Hypertension Research
Verified
Journal Article
Open access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
KCKeiichi Chin
Keiichi Chin
SUShinichi Umezawa
Shinichi Umezawa
SIShun Ito
Shun Ito
HYHareaki Yamamoto
Hareaki Yamamoto
KTKouichi Tamura
Kouichi Tamura
To prevent further spread of coronavirus disease 2019 (COVID-19), the Japanese government announced a state of emergency, resulting in major stress for the population. The aim of this study was to investigate a possible association between changes in daily stress and blood pressure (BP) in Japanese patients. We retrospectively investigated 748 patients with chronic disease who were treated by the Sagamihara Physicians Association to determine changes in stress during the COVID-19 state of emergency from 7 April to 31 May 2020. During the state of emergency, office BP significantly increased from 136.5 ± 17.5/78.2 ± 12.0 to 138.6 ± 18.6/79.0 ± 12.2 (p < 0.001 and p = 0.03, respectively). In contrast, home BP significantly decreased from 128.2 ± 10.3/75.8 ± 8.8 to 126.9 ± 10.2/75.2 ± 9.0 (p < 0.001 and p = 0.01, respectively), and the ratio of white coat hypertension was significantly increased (p < 0.001). Fifty-eight percent of patients worried about adverse effects of hypertension as a condition contributing to the severity and poor prognosis of COVID-19; decreased amounts of exercise and worsened diet compositions were observed in 39% and 17% of patients, respectively. In conclusion, a significant increase in office BP with the white coat phenomenon was observed during the state of emergency, as well as an increase in related stress. To prevent cardiovascular events, general practitioners should pay more attention to BP management during stressful global events, including the COVID-19 pandemic.

2 August 2023 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
KCKeiichi Chin
Keiichi Chin
NHNobuo Hatori
Nobuo Hatori
TFTakayuki Furuki
Takayuki Furuki
HSHiroyuki Sakai
Hiroyuki Sakai
AKAkira Kanamori
Akira Kanamori

4 October 2018 in Diabetes & Vascular Disease Research
Verified
Journal Article
Open access
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
MTMasao Toyoda
Masao Toyoda
MKMoritsugu Kimura
Moritsugu Kimura
NHNobuo Hatori
Nobuo Hatori
TFTakayuki Furuki
Takayuki Furuki
MMMasaaki Miyakawa
Masaaki Miyakawa
Aim: The aim of this study was to assess the renal effects of the glucose-lowering SGLT2 inhibitors in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Methods: The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. Clinical data of type 2 diabetes mellitus patients with chronic kidney disease, who were prescribed SGLT2 inhibitors in addition to other treatments, were collected and analysed. Results: SGLT2i was associated with a fall in HbA1c from 64.1 ± 16.7 mmol/mol (8.0 ± 1.5%) to 56.5 ± 12.9 mmol/mol (7.3 ± 1.2%) ( p < 0.01) in 869 analysed cases, a decrease in urine albumin-creatinine ratio from a median of 47.1 to 41.1 mg/gCr, and decrease in estimated glomerular filtration rate from 77.7 ± 23.9 to 75.0 ± 23.9 mL/min/1.73 m2 ( p < 0.01). The effect on albumin-creatinine ratio was independent of age or stage of estimated glomerular filtration; however, there was a significant negative correlation between albumin-creatinine ratio at the initiation of SGLT2 inhibitor and change in ACR. Multiple linear regression analysis identified use of empagliflozin, β-blockers, and sulphonylureas, Δsystolic blood pressure at office, serum Cr and albumin-creatinine ratio value at initiation of SGLT2 inhibitor as independent and significant determinants of change in ACR. Conclusions: This study confirmed that the beneficial renal effects of SGLT2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease, similar to those reported in large-scale clinical trials conducted in Western countries.

27 March 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YMYoshimi Muta
Yoshimi Muta
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
Masao ToyodaMasao Toyoda
Masao Toyoda
ATAtsuhito Tone
Atsuhito Tone
DSDaisuke Suzuki
Daisuke Suzuki
DKDaiji Kawanami
Daiji Kawanami
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients with type 2 diabetes (T2D). We previously reported that in combination therapy of SGLT2i and GLP1Ra, the effect on the renal composite outcome did not differ according to the preceding drug. However, it remains unclear how the initiation of combination therapy is associated with the renal function depending on the preceding drug. In this post hoc analysis, we analyzed a total of 643 T2D patients (GLP1Ra-preceding group, n = 331; SGLT2i-preceding group, n = 312) and investigated the differences in annual eGFR decline. Multiple imputation and propensity score matching were performed to compare the annual eGFR decline. The reduction in annual eGFR decline in the SGLT2i-preceding group (pre: −3.5 ± 9.4 mL/min/1.73 m2/year, post: −0.4 ± 6.3 mL/min/1.73 m2/year, p < 0.001), was significantly smaller after the initiation of GLP1Ra, whereas the GLP1Ra-preceding group tended to slow the eGFR decline but not to a statistically significant extent (pre: −2.0 ± 10.9 mL/min/1.73 m2/year, post: −1.8 ± 5.4 mL/min/1.73 m2/year, p = 0.83) after the initiation of SGLT2i. After the addition of GLP1Ra to SGLT2i-treated patients, slower annual eGFR decline was observed. Our data raise the possibility that the renal benefits—especially annual eGFR decline—of combination therapy with SGLT2i and GLP1Ra may be affected by the preceding drug.

5 February 2022 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
MTMasao Toyoda
Masao Toyoda
NHNobuo Hatori
Nobuo Hatori
HSHiroyuki Sakai
Hiroyuki Sakai
TFTakayuki Furuki
Takayuki Furuki
AKAkira Kanamori
Akira Kanamori

28 January 2021 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
Masao ToyodaMasao Toyoda
Masao Toyoda
NHNobuo Hatori
Nobuo Hatori
NSNobumichi Saito
Nobumichi Saito
TKTomohiko Kanaoka
Tomohiko Kanaoka
AKAkira Kanamori
Akira Kanamori
Aim: Sodium–glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD). Materials and Methods: The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for >1 year. Results: A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of urine albumin–creatinine ratio (LNACR) decreased significantly from 1.60 ± 0.65 to 1.51 ± 0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change in (Δ) diastolic blood pressure, and Δ hemoglobin A1c were independently correlated with ΔLNACR ( P < 0.001). The decrease in the LNACR was significantly smaller in the patients with estimated glomerular filtration rate (eGFR) [mL/(min ·1.73 m 2 )] of <60 ( P < 0.05). The eGFR decreased from 77.4 ± 22.3 to 72.7 ± 22.5 mL/(min ·1.73 m 2 ) ( P < 0.001). The multiple linear regression analysis showed that the LNACR at the initiation of treatment, Δbody weight at the previous survey, ΔeGFR at the previous survey, and the eGFR at the initiation of treatment correlated independently with ΔeGFR during the maintenance period ( P < 0.001). Greater changes in the eGFR during the maintenance period were observed in the patients with macroalbuminuria or eGFR of <60 ( P < 0.01). Conclusions: The study confirmed that the long-term use of six types of SGLT2i improved the albumin–creatinine ratio (ACR), although the eGFR gradually decreased during the treatment. The change in the ACR was significantly smaller in the patients with eGFR of 60 mL/(min ·1.73 m 2 ). However, this was a retrospective observational study; further studies are needed to formulate final conclusions.